Delphia (USA)’s Apellis Pharmaceuticals APLS Stock Holding History

Delphia (USA)’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-6,211	Closed	-$281K	–	298
2022 Q2	$281K	Buy	+6,211	New	+$283K	0.19%	192

Other funds holding APLS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Delphia (USA)'s APLS Position: Q3 2022 in Review

Delphia (USA) sold out of Apellis Pharmaceuticals (APLS) in Q3 2022, closing a stake of 6,211 shares — an estimated $281K sold.

Delphia (USA) first reported a position in APLS in Q2 2022 and held it in 1 quarter. The position peaked at $281K in Q2 2022. 250 funds tracked by Wall St. Rank hold APLS as of Q3 2022.

Delphia (USA) reported no remaining Apellis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Delphia (USA) sold 6,211 Apellis Pharmaceuticals shares in Q3 2022, an estimated $281K.
Delphia (USA) first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Delphia (USA)'s Apellis Pharmaceuticals position peaked at $281K in Q2 2022.
250 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2022.

Based on Delphia (USA)'s 13F filing for Q3 2022, filed 14 Nov 2022.